Topics:
Gastrointestinal Cancers • Medical Oncology • Cholangiocarcinoma • Journal Club ft. NEJM publications
Do you offer durvalumab in combination with gemcitabine and cisplatin in patients with metastatic ampullary adenocarcinoma, given the fact that ABC-02 trial included patients with ampullary adenocarcinoma while TOPAZ trial excluded those patients?
Answer from: Medical Oncologist at Community Practice
Unfortunately we don't have robust contemporary data for ampullary adenocarcinoma. In general I would not apply the TOPAZ-1 study findings to this population.
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I do not.